




| | | EMLc | ATC codes: B01AA03 |
|---|---|---------------------------|--------------------|
| Indication | Cerebral ischaemic stroke due to embolic occlusion | ICD11 code: 8B11.2 | |
| INN | Warfarin | | |
| Medicine type | Chemical agent | | |
| List type | Core (EML) Complementary (EMLc) | | |
| Formulations | Oral > Solid: 5 mg (sodium salt) ; 1 mg (sodium salt) ; 2 mg (sodium salt) ; 0.5 mg (sodium salt) (EMLc) | | |
| EML status history | First added in 1977 (TRS 615) Changed in 1979 (TRS 641) Changed in 1982 (TRS 685) Changed in 1987 (TRS 770) Changed in 2007 (TRS 950) Changed in 2021 (TRS 1035) | | |
| Sex | All | | |
| Age | Also recommended for children | | |
| Therapeutic alternatives | Medicines within the same pharmacological class can be used | | |
| Therapeutic alternatives limitations | Therapeutic alternatives to be reviewed (2023) | | |
| Therapeutic alternatives limitations for EMLc | Therapeutic alternatives to be reviewed (2023) | | |
| Patent information | Patents have expired in most jurisdictions Read more about patents.  | | |
| Wikipedia | Warfarin  | | |
| DrugBank | Warfarin  | | |

Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended the therapeutic alternatives for warfarin be reviewed.

